Article
A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
Study Evaluates Training Tool Developed for PCP Psoriasis Diagnosis
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Conference Speaker Sneak Peek: Elevate-Derm
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Tirbanibulin Demonstrates Efficacy for Actinic Keratosis in Larger Field Treatment
Safe and Effective: Upadacitinib Shows Promise in PN Treatment